UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™ reverse thermal hydrogel, a novel technology that is liquid when chilled, but gels at body temperature. We believe RTGel technology has the potential to be applied to a variety of unmet medical needs where increased exposure to the active drug would improve the therapeutic profile of existing drugs, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to potentially chemoablate tumors, a method that utilizes intervention without surgical removal or resection, and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.